Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (1167)	11/2/1999 10:27:00 AM
From: Mark Bong	Read Replies (1) \| Respond to of 1686

Harold, The Immune Response Corporation has a phase 2 trial for a psoriasis therapeutic vaccine, however after two years, they have not progressed beyond Phase II so I am assuming that either they have an inferior product or they do not have the resources to continue to develop it. Based upon their restructuring announcement recently, it looks like they will focus mainly upon REMUNE, their drug candidate that has shown efficacy in reconstituting the immune system of HIV positive individuals. REMUNE is licensed to AGPH and its new parent, Warner Lambert. A good post about this drug and its current status can be found at their message board on Yahoo. messages.yahoo.com messages.yahoo.com The following post deals with IMNR restructuring. biz.yahoo.com Nice talking with you last night, and many thanks for the competitor info. I will send you some additional information.